Expert Systems and Traws Pharma report breakthrough in H5N1Bird Flu antivirus by Investing.com

SAN DIEGO, January 10, 2025 /PRNewswire/ — Expert Systems, an artificial intelligence-enabled hybrid drug discovery and development accelerator, has announced a significant development milestone Traws Pharma, Inc. (NASDAQ: TRAW) H5N1 antivirus program. Investigational drug, Tivoxavir Marboxilhas shown encouraging results as a single-dose treatment for H5N1 avian influenza, representing a potentially key advance in addressing this serious health challenge.

Tivoxavir Marboxilan oral drop-dependent endonuclease inhibitor targeting the highly conserved influenza protein, showing broad-spectrum efficacy against a variety of influenza strains, including avian influenza. Preclinical studies have highlighted its potent activity against drug-resistant and highly pathogenic avian influenza viruses, as in vitro and in vivo.

In a recent randomized, double-blind, placebo-controlled phase 1 clinical trial, the safety, tolerability, and pharmacokinetics of individual ascending doses Tivoxavir Marboxil were evaluated in healthy adult volunteers negative for influenza. The trial reported no treatment-related adverse events. Notably, a single dose maintained plasma drug levels above the effective concentration (EC90) for more than 23 days, indicating the potential for sustained efficacy with single administration.

dr. Robert R. Redfieldchief Medical (TASE:) Clerk for Traws Pharma and former director US Centers for Disease Control and Prevention (CDC), commented: “The spread of avian influenza in wild and domestic animal populations, including mammals, poses an increasing risk for adaptation to humans and subsequent spread in the population. With the increasing number of human infections and recent reports of severe cases, we should be warn of the ever-increasing possibility of the spread of an epidemic or pandemic of bird flu.”

Expert Systems played a key role in the ideation, design, incubation and support of this program, taking advantage of its hybrid platform for drug discovery, development and study launch for hybrid human-AI-based risk studies. This collaboration highlights the effectiveness of integrating artificial intelligence with human expertise and computer-aided drug design and business management to accelerate the development of innovative therapies.

“Success Tivoxavir Marboxil highlights the transformative potential of combining artificial intelligence with human expertise to address pressing global health challenges,” he said Tudor Opreachief executive officer of Expert Systems. “We are excited to support Traws Pharma in bringing this innovative flu treatment to market.”

Following the completion of phase 1 trials, plans are underway to initiate phase 2 efficacy studies in the first half of 2025. This brings Tivoxavir Marboxil closer to becoming a viable treatment option for H5N1 avian influenza, addressing critical global health needs.

About Traws Pharma
Traws Pharma, Inc. is a clinical biopharmaceutical company dedicated to the development of oral small molecule therapies for respiratory viral diseases and cancer. Using expertise in small molecule chemistry, artificial intelligence and streamlined development processes, Traws Pharma focuses on creating innovative medicines targeting critical health threats, including drug-resistant influenza viruses and bird flu.

https://www.trawspharma.com/

About expert systems
Expert Systems is an accelerator of drug discovery and development and a leader in computer-enabled discovery and development platforms, committed to advancing the development of innovative therapies that address critical unmet medical needs. Combining advanced machine learning algorithms with broad domain expertise, Expert Systems accelerates the development of life-saving treatments in infectious diseases, oncology, CNS, immune and cardiometabolic diseases. The company’s innovative approach is reshaping the future of therapy.

https://www.expertsystems.inc/

Media contact:Bill FarleyChief Business Officer
bfarley@expertsystems.inc